Table 2.
Quality of sleep in patients postpancreaticoduodenectomy.
| Variable | PSQI score > 5 (n = 22) | ||
|---|---|---|---|
| Age, mean ± SD | 65.4 ± 11.0 | ||
| Gender, n (%) | Male | 15 (65.4%) | |
| Female | 7 (27.3%) | ||
| BMI, mean ± SD | 25.5 ± 5.7 | ||
| Smoking, n (%) | 6 (27.3%) | ||
| Alcohol consumption, n (%) | 4 (18.2%) | ||
| Caffeine intake, n (%) | 9 (40.9%) | ||
| Physical activity, n (%) | 11 (50.0%) | ||
| Comorbidities, n (%) | Diabetes | 11 (50.0%) | |
| COPD | 1 (4.5%) | ||
| CVD | 14 (63.6%) | ||
| CKD | 2 (9.1%) | ||
| Tumor characteristics, n (%) | Grade | 1 | 3 (13.6%) |
| 2 | 14 (63.6%) | ||
| 3 | 4 (18.2%) | ||
| 4 | 0 | ||
| T stage | 1 | 4 (18.2%) | |
| 2 | 12 (54.5%) | ||
| 3 | 6 (37.3%) | ||
| 4 | 0 | ||
| N stage | 0 | 6 (27.3%) | |
| 1 | 10 (45.5%) | ||
| 2 | 6 (27.3%) | ||
| M stage | 0 | 20 (90.9%) | |
| 1 | 2 (9.1%) | ||
| Tumor size, mean ± SD | 2.9 ± 1.4 | ||
| Treatment regimen, n (%) | Adjuvant chemotherapy | 13 (59.1%) | |
| Neoadjuvant chemotherapy | 2 (9.1%) | ||
| Adjuvant radiotherapy | 0 | ||
| Neoadjuvant radiotherapy | 0 | ||
| No chemotherapy or radiotherapy | 7 (31.8%) | ||
| All-cause mortality, n (%) | 2 (11.1%) | ||
BMI: body mass index; COPD: chronic obstructive pulmonary disease; CVD: cardiovascular disease; CKD: chronic kidney disease; PSQI: Pittsburgh Sleep Quality Index.